Stefano Romeo is Professor in Molecular and Clinical Medicine at the Sahlgrenska Academy in the Institute of Medicine at Gothenburg University and Senior Consultant in Endocrinology and Metabolism at the Department of Cardiology at Sahlgrenska University Hospital in Gothenburg. Dr Romeo’s main research focus is the role of genetic variants in modulating metabolic liver disease and serum lipid levels. His research field ranges from genetic association studies in large cohorts to understanding molecular mechanisms underlying the genetic associations. His main clinical commitment is to drive the Lipid Clinic at Sahlgrenska University Hospital in Gothenburg.

Contributions

LCN webinar on EAS SMD consensus - BrazilLCN WebinarsLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – PakistanLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – LithuaniaLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – Czech RepublicLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – ItalyLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – GeorgiaLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – EstoniaLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – UzbekistanWebinars on-demandLCN WebinarsLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – IraqLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – PortugalLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – KazakhstanLCN WebinarsWebinars on-demandLipid Clinic NetworkLCN Consensus Statement on SMD Webinar – LatviaLCN WebinarsWebinars on-demandLipid Clinic NetworkWebinar on Homozygous Familial Hypercholesterolemia Management (1/3) - Implementing current guidanceRare Disease DayHoFH Awareness DayWebinars on-demandClinical staging to guide management of metabolic disorders and their sequelae: A European Atherosclerosis Society consensus statementWebinars on-demandRedefining Steatotic Liver Disease to identify novel targets to treat cardiovascular diseaseWorkshop: New targets for therapyClinical Staging To Guide Actionable Management Of Systemic Metabolic Disorders And Their Sequelae: A European Atherosclerosis Society Consensus StatementLate Breaker Session: ClinicalClinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statementPublicationConsensus paperRLD 2024 Greece 17 - Q&A - Chylomicronemia syndromeEAS RLD 2024 AthensRLD 2024 Greece - 16 - Chylomicronemia syndromeEAS RLD 2024 AthensEAS Advanced Course – Rare Lipid Disorders – Sweden & NorwayWebinars on-demandHypocholesterolemia friend or foe?Webinars on-demandDebate session - HDL: In search for a function - Discussion and Q&ADebate session - HDL: In search for a function90th EAS Congress 2022IAS/EAS joint session - What is the environment doing to our health? - Discussion and Q&A90th EAS Congress 2022IAS/EAS joint session - What is the environment doing to our health?Understanding lipoprotein(a) in cardiovascular diseaseWebinars on-demandFatty Liver and Cardiovascular Disease: Partners in Crime?Webinars on-demandANGLT3 biology and genetics89th EAS Congress 2021(ReviewAngPTL3DyslipidemiaLipidologyMetab lipoCombined hypocholesterolemiaHypolipidemia)Genetics of FH mutation and distributionEAS AC on FHAn introduction to Familial Hypercholesterolaemia for cliniciansAn introduction to FH for cliniciansThe metabolic basis of FCSRare Disease Day87th EAS Congress 2019Genes can hurt you to develop CVD beyond classical risk factors86th EAS Congress 2018